Navigation Links
Beckman Coulter Announces Licensing Option Agreements for Cancer Genes with Johns Hopkins University
Date:10/30/2007

Contracts Establish Exclusive Access to Diagnostic Application of Research

Discoveries

FULLERTON, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC) announced today that it has signed two agreements with Johns Hopkins University giving the company exclusive options to license cancer genomics intellectual property. The first agreement covers 200 genes linked to breast and colon cancer, discovered in a landmark study published last year by researchers at Johns Hopkins Kimmel Cancer Center. Beckman Coulter Agencourt subsidiary's Genomic Services performed the sequencing for this study, which was co-authored by James Hartigan, an Agencourt project manager. The second agreement covers sequencing services and options to license genomic intellectual property from current studies on six additional cancers.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

"These unprecedented agreements put Beckman Coulter in a unique, leading- edge position in the molecular diagnostics field," commented Bruce Wallace, vice president of Beckman Coulter's Molecular Diagnostics Business Center. "Beckman Coulter will have the exclusive option to license any of the genetic mutations discovered in these studies that have diagnostic potential. Given the leadership role Johns Hopkins is playing in cancer genetics, our relationship with them will help propel us to the forefront of this rapidly developing field."

With these new agreements, Beckman Coulter will have first access to Johns Hopkins cancer study data. The company's molecular diagnostics assay group is already evaluating the breast and colon cancer genes. "The success of our strategic plan is dependent in part on our development of a robust molecular diagnostics business," Wallace continued. "We are already in the process of moving our research genomics technologies into platforms for diagnostic use. Building content, or approved tests for that platform, from research such as the John Hopkins cancer genomics studies, will enhance our success."

Agencourt Bioscience Corporation, a wholly owned subsidiary of Beckman Coulter, is a leading provider of nucleic acid purification products and genomic services for life science research. The company's products and services are based on the patented Agencourt SPRI(R) (Solid Phase Reversible Immobilization) paramagnetic bead-based technology.

Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents more than 75 percent of the company's 2006 annual revenue of $2.53 billion. For more information, visit http://www.beckmancoulter.com.

Contacts: Mary Luthy

Corporate Communications, Beckman Coulter

Phone: (714) 993-8770

E-mail: mluthy@beckman.com

Robert Raynor, Ph.D.

Investor Relations, Beckman Coulter

Phone: (714) 773-7620

E-mail: rraynor@beckman.com


'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF ... the greater Houston Area. The new location is located at 2255 E. Mossy Oaks ... Springwoods Village. This newest location will provide patients living in the north Houston area ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Road in Building 2. The clinic is the group’s second in New Braunfels and ... the company’s second New Braunfels location brings things full circle for the group, “It’s ...
(Date:3/23/2017)... ... , ... The IoT (Internet of Things) is revolutionizing the way the world ... businesses and individual consumers alike. Laboratories can maximize their profit margin by increasing ... $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects the IoT ...
(Date:3/23/2017)... , ... March 23, 2017 , ... 82% of adults are unaware of the dangers ... not brush their teeth the minimum two times a day that dentists recommend. The ramifications ... 51 million hours of school and adults missing 164 million hours of work each year ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and thank ... Every day, two kidneys filter about 120 to 150 quarts of blood. Put another ... regulating fluid levels and blood pressure, supporting bone health and promoting red blood cell ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017 FinancialBuzz.com News Commentary  ... According to new ... market research, the legal cannabis market is projected to continue ... conflicting signals from the current presidential administration. The report created ... biggest drivers of growth in this industry are the passage ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced the ... report to their offering. ... The IPF pipeline is very strong with a total of 97 ... Inc., Biogen and Sanofi are involved in the development of the IPF ... is in Phase III stage, 15 are in Phase II stage, 12 ...
(Date:3/24/2017)... , March 24, 2017 A ReportsnReports.com ... has been growing rapidly as the global sales of Adcetris and ... growth in the antibody drug conjugates market is driven by large ... cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, ...
Breaking Medicine Technology: